Drug industry
Article Abstract:
The drug industry had a good year in 1999 and the year 2000 is also expected to be profitable, although earnings will be slightly lower. The industry is also consolidating and the debate over Medicare in the presidential campaign in the year 2000 will also have an affect on the industry. Investors need to seek those stocks with good margins and rising product lines.
Author: Rho, George, Espaillat, Joseph, Jones, Stephen E., Mitkowski, Robert, Jr., Ferro, Mario, Romaine, Sigourney B., Schlein, Milton, Feenan, Gerard, Harris, Frederick L., III, Clark, Charles, Gallen, David, Butler, Jeremy J., Markey, Keith A.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2000
SmithKline Beecham PLC, American Home Products Corp., BARR Laboratories Inc., Dura Pharmaceuticals Inc., Elan Corporation PLC, Gilead Sciences Inc., ICN Pharmaceuticals Inc., Merck and Company Inc., Millennium Pharmaceuticals Inc., DURA, ELN, GILD, MLNM
Drug industry
Article Abstract:
Operational basics and earnings for the pharmaceutical industry remain good for 1999 and this scenario is expected to remain in place for the near-term future. However, the stocks in this industry have declined in their timeliness rating, due in part to sector rotation into cyclical issues, despite the 19.9% increase in the Dow Jones Industrial Average since the beginning of 1999. Investors need to seek the highest quality stocks during periods of price weakness in this industry.
Author: Rho, George, Jones, Stephen E., Mitkowski, Robert, Jr., Ferro, Mario, Romaine, Sigourney B., Schlein, Milton, Feenan, Gerard, Harris, Frederick L., III, Clark, Charles, Gallen, David, Markey, Keith A., Gagas, Adam C., Owens, Victoria, Butler, Jerome J.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1999
SmithKline Beecham Group PLC
Drug industry
Article Abstract:
Earnings and profits for the drug industry have been good for the second half of 1999 and this trend is expected to continue for the next ten years, as well, price hikes have a better environment, also. However, some drugs are losing patent protection in the coming years, and drug industry stock prices have fallen during 1999. These stocks are timely for investors due to good earnings and demographic trends in 1999 and later.
Author: Rho, George, Espaillat, Joseph, Jones, Stephen E., Markovich, Steven, Reaves, Constance M., Galeotafiore, Carrie, Mitkowski, Robert, Jr., Ferro, Mario, Romaine, Sigourney B., Schlein, Milton, Feenan, Gerard, Clark, Charles, Gallen, David, Butler, Jeremy J., Markey, Keith A., Harris, Frederick L, III
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1999
World, SmithKline Beecham Corp. (Philadelphia, Pennsylvania)
Subjects list: United Kingdom, Statistical Data Included, United States, Pharmaceutical industry, Drugs, Securities, Eli Lilly and Co., Pfizer Inc., Monsanto Co., Pharmacia and Upjohn Inc., MTC, PNU, Glaxo Wellcome PLC, Warner-Lambert Co., Biogen Inc., Bristol-Myers Squibb Co., ALZA Corp., Amgen Inc., Block Drug Company Inc., Chiron Corp., Covance Inc., Cygnus Inc., Forest Laboratories Inc., Genzyme Corp., Human Genome Sciences Inc., IDEC Pharmaceuticals Corp., Immunex Corp., Inhale Therapeutic Systems Inc., IVAX Corp., Jones Pharma Inc., MedImmune Inc., Mylan Laboratories Inc., PAREXEL International Corp., Perrigo Co., Pharmaceutical Product Development Inc., Quintiles Transnational Corp., Schering-Plough Corp., Sicor Inc., Watson Pharmaceuticals Inc., AZA, AHP, AMGN, BRL, BGEN, BLOCA, BMY, CHIR, CVD, CYGN, FRX, GENZ, HGSI, ICN, IDPH, IMNX, INHL, IVX, JMED, LLY, MEDI, MLY, PRXL, PRGO, PFE, PPDI, QTRN, SGP, SCRI, WLA, WPI, Valeant Pharmaceuticals International, Wyeth, Merck & Company Inc., Barr Laboratories Inc., Roberts Pharmaceutical Corp., RPCX, Immunetech Pharmaceuticals Inc. Dura Pharmaceuticals, Elan Corp
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
